Case Report: Reversal of Integrase Inhibitor– and Tenofovir Alafenamide–Related Weight Gain After Switching Back to Efavirenz/Emtricitabine/Tenofovir DF
| Autor: | Mehri S McKellar, Kara S. McGee, F Will Pohlman |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Efavirenz
Integrase inhibitor Emtricitabine Tenofovir alafenamide chemistry.chemical_compound immune system diseases Medicine Novel ID Cases tenofovir alafenamide biology business.industry Elvitegravir Cobicistat HIV virus diseases weight gain Virology Integrase Editor's Choice AcademicSubjects/MED00290 Infectious Diseases Oncology chemistry biology.protein integrase medicine.symptom business Weight gain medicine.drug |
| Zdroj: | Open Forum Infectious Diseases |
| ISSN: | 2328-8957 |
| DOI: | 10.1093/ofid/ofab403 |
| Popis: | We report a case of substantial weight gain in a virologically suppressed patient with HIV after changing his antiretroviral therapy from efavirenz/emtricitabine/tenofovir DF to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide with subsequent rapid weight loss upon switching back. The role of antiretrovirals in weight gain and loss and patient- and HIV-specific factors are discussed. Antiretroviral therapy may be associated with weight gain, sometimes substantial. We report a case of reversal of substantial weight gain associated with INSTI/TAF use upon switching back to EFV/FTC/TDF and discuss weight effects of antiretroviral therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|